DocMorris AG

DOCM

CH0042615283

Drug Retailers

Market Closed - Swiss Exchange Other stock markets 11:30:41 2025-07-09 am EDT			5-day change	1st Jan Change
7.210 ^CHF	+8.42%		+6.74%	-63.91%

Jul. 03	DOCMORRIS : Deutsche Bank reaffirms its Neutral rating	ZD
Jul. 02	Court Ruling: High-Value Vouchers for E-Prescriptions Deemed Unlawful	DP

DOCMORRIS : Deutsche Bank reaffirms its Neutral rating

Published on 04/15/2025 at 07:07, updated on 04/15/2025 at 07:54

Deutsche Bank analyst Jan Koch maintains his Neutral opinion on the stock. The target price remains set at CHF 20.

Latest news about DocMorris AG

DOCMORRIS : Deutsche Bank reaffirms its Neutral rating	Jul. 03	ZD
Court Ruling: High-Value Vouchers for E-Prescriptions Deemed Unlawful	Jul. 02	DP
North Rhine-Westphalian Health Minister wants to strengthen pharmacies	Jun. 09	DP
DOCMORRIS : Jefferies reiterates its Buy rating	Jun. 04	ZD
DOCMORRIS : Upgraded from Sell to Buy by Baader Bank	Jun. 03	ZD
DOCMORRIS : Hauck & Aufhauser reiterates its Buy rating	May. 27	ZD
DOCMORRIS : Jefferies keeps its Buy rating	May. 26	ZD
Swiss stocks - Factors to watch on May 22	May. 22	RE
DocMorris Expects CHF200 Million from Rights Offering	May. 22	MT
Docmorris Announces Number Of Shares Sold In Rights Offering	May. 21	RE
Swiss Equities Close Higher; DocMorris Shares Jump	May. 20	MT
Pelion Takes Minority Stake in DocMorris	May. 20	MT
Docmorris Was Informed By Pelion That It Has Acquired A Stake Of 9.68% In Docmorris	May. 20	RE
DocMorris AG announced that it expects to receive funding from Pelion S.A.	May. 19	CI
DOCMORRIS : Warburg Research reiterates its Neutral rating	May. 12	ZD
DocMorris Shareholders Approve Capital Increase Proposal	May. 08	MT
DOCMORRIS : Sell rating from Baader Bank	May. 08	ZD
DocMorris AG Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 07	CI
Redcare Pharmacy back in profit as expected – share price down	May. 06	DP
Redcare Pharmacy wants to grow without acquisitions	Apr. 24	DP
Swiss stocks - Factors to watch on April 17	Apr. 17	RE
DOCMORRIS : Baader Bank lowers its rating to Sell	Apr. 16	ZD
DOCMORRIS : Deutsche Bank reaffirms its Neutral rating	Apr. 15	ZD
DOCMORRIS : Gets a Neutral rating from Warburg Research	Apr. 14	ZD
DOCMORRIS : Gets a Neutral rating from Deutsche Bank	Apr. 11	ZD

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Employees

1,454

Sector

Drug Retailers

Calendar

Aug. 19 - Q2 2025 Earnings Release

More about the company